PortfoliosLab logo
GSK vs. SHEL
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between GSK and SHEL is 0.45, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.0
Correlation: 0.5

Performance

GSK vs. SHEL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in GlaxoSmithKline plc (GSK) and Shell plc (SHEL). The values are adjusted to include any dividend payments, if applicable.

80.00%100.00%120.00%140.00%160.00%180.00%NovemberDecember2025FebruaryMarchApril
101.96%
159.51%
GSK
SHEL

Key characteristics

Sharpe Ratio

GSK:

-0.21

SHEL:

-0.26

Sortino Ratio

GSK:

-0.12

SHEL:

-0.19

Omega Ratio

GSK:

0.99

SHEL:

0.97

Calmar Ratio

GSK:

-0.19

SHEL:

-0.31

Martin Ratio

GSK:

-0.34

SHEL:

-0.76

Ulcer Index

GSK:

16.11%

SHEL:

7.60%

Daily Std Dev

GSK:

26.51%

SHEL:

22.77%

Max Drawdown

GSK:

-55.21%

SHEL:

-67.46%

Current Drawdown

GSK:

-15.61%

SHEL:

-10.14%

Fundamentals

Market Cap

GSK:

$75.93B

SHEL:

$193.60B

EPS

GSK:

$1.65

SHEL:

$5.06

PE Ratio

GSK:

22.73

SHEL:

12.86

PEG Ratio

GSK:

0.36

SHEL:

2.51

PS Ratio

GSK:

2.42

SHEL:

0.68

PB Ratio

GSK:

4.19

SHEL:

1.09

Total Revenue (TTM)

GSK:

$24.01B

SHEL:

$211.83B

Gross Profit (TTM)

GSK:

$16.98B

SHEL:

$39.88B

EBITDA (TTM)

GSK:

$5.14B

SHEL:

$41.36B

Returns By Period

In the year-to-date period, GSK achieves a 11.89% return, which is significantly higher than SHEL's 6.25% return. Over the past 10 years, GSK has underperformed SHEL with an annualized return of 2.53%, while SHEL has yielded a comparatively higher 5.39% annualized return.


GSK

YTD

11.89%

1M

-2.30%

6M

2.01%

1Y

-4.78%

5Y*

1.57%

10Y*

2.53%

SHEL

YTD

6.25%

1M

-9.82%

6M

0.63%

1Y

-6.44%

5Y*

18.04%

10Y*

5.39%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

GSK vs. SHEL — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GSK
The Risk-Adjusted Performance Rank of GSK is 3838
Overall Rank
The Sharpe Ratio Rank of GSK is 4040
Sharpe Ratio Rank
The Sortino Ratio Rank of GSK is 3434
Sortino Ratio Rank
The Omega Ratio Rank of GSK is 3434
Omega Ratio Rank
The Calmar Ratio Rank of GSK is 3939
Calmar Ratio Rank
The Martin Ratio Rank of GSK is 4545
Martin Ratio Rank

SHEL
The Risk-Adjusted Performance Rank of SHEL is 3333
Overall Rank
The Sharpe Ratio Rank of SHEL is 3838
Sharpe Ratio Rank
The Sortino Ratio Rank of SHEL is 3232
Sortino Ratio Rank
The Omega Ratio Rank of SHEL is 3131
Omega Ratio Rank
The Calmar Ratio Rank of SHEL is 3232
Calmar Ratio Rank
The Martin Ratio Rank of SHEL is 3535
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

GSK vs. SHEL - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and Shell plc (SHEL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for GSK, currently valued at -0.21, compared to the broader market-2.00-1.000.001.002.003.00
GSK: -0.21
SHEL: -0.26
The chart of Sortino ratio for GSK, currently valued at -0.12, compared to the broader market-6.00-4.00-2.000.002.004.00
GSK: -0.12
SHEL: -0.19
The chart of Omega ratio for GSK, currently valued at 0.99, compared to the broader market0.501.001.502.00
GSK: 0.99
SHEL: 0.97
The chart of Calmar ratio for GSK, currently valued at -0.19, compared to the broader market0.001.002.003.004.005.00
GSK: -0.19
SHEL: -0.31
The chart of Martin ratio for GSK, currently valued at -0.34, compared to the broader market-5.000.005.0010.0015.0020.00
GSK: -0.34
SHEL: -0.76

The current GSK Sharpe Ratio is -0.21, which is comparable to the SHEL Sharpe Ratio of -0.26. The chart below compares the historical Sharpe Ratios of GSK and SHEL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.00NovemberDecember2025FebruaryMarchApril
-0.21
-0.26
GSK
SHEL

Dividends

GSK vs. SHEL - Dividend Comparison

GSK's dividend yield for the trailing twelve months is around 4.15%, less than SHEL's 4.22% yield.


TTM20242023202220212020201920182017201620152014
GSK
GlaxoSmithKline plc
4.15%4.60%3.75%4.78%4.92%5.49%4.28%5.55%5.72%7.06%5.96%6.09%
SHEL
Shell plc
4.22%4.39%3.76%3.48%3.78%5.44%6.14%5.48%4.79%5.88%6.98%4.72%

Drawdowns

GSK vs. SHEL - Drawdown Comparison

The maximum GSK drawdown since its inception was -55.21%, smaller than the maximum SHEL drawdown of -67.46%. Use the drawdown chart below to compare losses from any high point for GSK and SHEL. For additional features, visit the drawdowns tool.


-30.00%-25.00%-20.00%-15.00%-10.00%-5.00%0.00%NovemberDecember2025FebruaryMarchApril
-15.61%
-10.14%
GSK
SHEL

Volatility

GSK vs. SHEL - Volatility Comparison

The current volatility for GlaxoSmithKline plc (GSK) is 11.15%, while Shell plc (SHEL) has a volatility of 15.38%. This indicates that GSK experiences smaller price fluctuations and is considered to be less risky than SHEL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


4.00%6.00%8.00%10.00%12.00%14.00%16.00%NovemberDecember2025FebruaryMarchApril
11.15%
15.38%
GSK
SHEL

Financials

GSK vs. SHEL - Financials Comparison

This section allows you to compare key financial metrics between GlaxoSmithKline plc and Shell plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items